home / stock / atai / atai news


ATAI News and Press, ATAI Life Sciences N.V. From 09/27/23

Stock Information

Company Name: ATAI Life Sciences N.V.
Stock Symbol: ATAI
Market: NASDAQ
Website: atai.life

Menu

ATAI ATAI Quote ATAI Short ATAI News ATAI Articles ATAI Message Board
Get ATAI Alerts

News, Short Squeeze, Breakout and More Instantly...

ATAI - Enthea Announces Nationwide Availability of Ketamine Treatment to Employees

Massachusetts-based healthcare provider Enthea has revealed that it is now offering psychedelic-assisted therapy coverage in employee healthcare plans nationwide . The provider was in the news last year when soap company Dr. Bronners announced that it would be offering psychedelic-assisted the...

ATAI - Psychedelics research amendments advance in House committee

2023-09-26 13:17:43 ET More on psychedelic drug development Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Qui...

ATAI - High Demand Characterizes Launch of Legal Psilocybin Access in Oregon

This June, America’s first-ever service center for psilocybin-assisted therapy opened in Oregon, marking both the state and country’s first definitive steps toward legalizing therapeutic psilocybin for the masses. Oregon is the first state in the country to offer psilocybin-rela...

ATAI - The Breakthrough Therapy Aiming To Solve The World's Mental Health Crisis

2023-09-19 08:00:18 ET FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – September 19, 2023 – Depression is costing the economy $1 trillion in lost production every single year. Yet, a classical compound that even the FDA has twi...

ATAI - With ecstasy a potential PTSD therapy, psychedelic treatments could take off

2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...

ATAI - Exploring Effects of Simultaneous Opioid, Psychedelic Use for Chronic Pain

Recent research investigating the interaction between psychedelics and opioids has found that using the two together to treat chronic pain may not be a good idea. Opioids have been the go-to treatment for pain disorders for a long time, but they have lost popularity over the past decade, especi...

ATAI - atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conferenc...

ATAI - California House Passes Psychedelics Bill, Resends to Senate

California Assembly members have approved a psychedelic legalization measure passed by the Senate before sending it back to the Senate for discussions on recent amendments. The bill could potentially land on Governor Gavin Newsom’s desk once it advances through the Senate, putting Califo...

ATAI - Timothy Leary Expounds on Five Stages Psychedelic Users Could Experience During a Trip

Even though psychedelics have been illegal since the 1970s, psychedelic use among people has surged in recent years , partly due to claims of psychedelics’ therapeutic properties and the fact that younger generations are increasingly moving away from alcohol and tobacco. For people look...

ATAI - Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies

2023-09-01 19:02:09 ET Summary Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated with schizophrenia, with top-line results expected in the 2nd half of 2024. The company is also working on advancing COMP360 for treatment-resistant depressio...

Previous 10 Next 10